Lenacapavir Named 'Breakthrough of the Year' for Advancing HIV Prevention

The injectable drug offers a twice-yearly alternative to daily pills, marking a significant step in global HIV prophylaxis efforts.

The prestigious journal 'Science' has recognized Lenacapavir as the most important scientific breakthrough of 2024 for its role in HIV prevention.
The drug is administered as a semi-annual injection, providing an effective and more convenient alternative to daily oral PrEP medications like Truvada.
Experts highlight the potential of Lenacapavir to improve access to HIV prevention, particularly in regions with high infection rates, such as sub-Saharan Africa.
The manufacturer, Gilead, plans to seek approval for Lenacapavir as an HIV prevention tool in multiple countries, with a focus on making it available in lower-income regions.
Currently, Lenacapavir is approved in the EU for treating certain HIV-positive patients, but its availability as a preventive option in places like Germany remains uncertain.